Results 1 to 10 of about 3,000 (187)

Pyrazinamide resistance in rifampicin discordant tuberculosis.

PLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase, Ravesh Singh, Khine Swe Swe-Han, Koleka Patience Mlisana   +3 more
doaj   +4 more sources

Relationship between rifampicin resistance and RpoB substitutions of Rhodococcus equi strains isolated in France

Journal of Global Antimicrobial Resistance, 2020
Objectives: Study of the rifampicin resistance of Rhodococcus equi strains isolated from French horses over a 20-year period. Methods: Rifampicin susceptibility was tested by disk diffusion (DD) and broth macrodilution methods, and rpoB gene sequencing ...
Sandrine Petry, Corinne Sévin, Sofia Kozak, Nathalie Foucher, Claire Laugier, Maud Linster, Marie-France Breuil, Marie-Capucine Dupuis, Aymeric Hans, Fabien Duquesne, Jackie Tapprest   +10 more
doaj   +3 more sources

Can resistance to either isoniazid or rifampicin predict multidrug resistance tuberculosis (MDR-TB)

Bulletin of the National Research Centre, 2023
Background Previous studies have shown significant differences and lack clarity on whether resistance to either isoniazid or rifampicin can predict multidrug resistance tuberculosis (MDR-TB).
Betty R. Mchaki, Fauster X. Mgaya, Peter P. Kunambi, Mecky I. Matee   +3 more
doaj   +2 more sources

Rifampicin resistance and risk factors associated with significantly lower recovery rates after two-stage revision in patients with prosthetic joint infection

Journal of Global Antimicrobial Resistance, 2022
Objectives: Rifampicin plays a key role in the management of prosthetic joint infections (PJIs); however, the emergence of rifampicin resistance is associated with less favourable clinical outcomes. The purpose of this study was to investigate the impact
Gergely Krizsan, Imre Sallai, Daniel Sandor Veres, Gyula Prinz, Donat Szeker, Gabor Skaliczki   +5 more
doaj   +3 more sources

Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis

Journal of Infection and Public Health, 2018
Rifampicin (RIF) plays a pivotal role in the treatment of tuberculosis due to its bactericidal effects. Because the action of RIF is on rpoB gene encoding RNA polymerase β subunit, 95% of RIF resistant mutations are present in rpoB gene. The majority of the mutations in rpoB gene are found within an 81bp RIF-resistance determining region (RRDR ...
Zaw Lin
exaly   +4 more sources

Rifampicin Resistance in Tuberculosis Outbreak, London, England

Emerging Infectious Diseases, 2005
Mycobacterium tuberculosis isolates cultured from 6 patients associated with an isoniazid-resistant M. tuberculosis outbreak acquired rifampicin resistance. The rpoB gene sequence showed that resistance was associated with rare mutations in each isolate.
Claire Jenkins, Alleyna P. Claxton, Robert J. Shorten, Timothy D. McHugh, Stephen H. Gillespie   +4 more
doaj   +4 more sources

Rifampicin Resistance by Xpert MTB/RIF Assay in Pulmonary Tuberculosis- Is there a Need for Confirmation by Retesting? [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Xpert Mycobacterium tuberculosis/Resistance to Rifampicin (MTB/RIF) assay detects MTB Complex (MTBC) and rifampicin resistance simultaneously. In high prevalence countries like India, detection of rifampicin resistance in sputum specimen of
Swapna Rajesh Kanade, Swati Vijay, Gita Nataraj   +2 more
doaj   +1 more source

Prevalence of rifampicin resistant pulmonary tuberculosis using geneXpert assay in Ethiopia, a systematic review and meta-analysis

Heliyon, 2023
Background: Drug-resistant tuberculosis continues to be a global public health threat. Ethiopia is one of the high-burden countries for tuberculosis and multi-drug resistant tuberculosis.
Maritu Demelash, Endalkachew Nibret, Tamirat Hailegebriel, Zebasil Minichil, Daniel Mekonnen   +4 more
doaj   +1 more source

Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients

Antibiotics, 2023
Background. Rifampicin is a pillar in the treatment of periprosthetic joint infection (PJI). However, rifampicin resistance is an increasing threat to PJI treatment.
Stergios Lazarinis, Nils P. Hailer, Josef D. Järhult, Anders Brüggemann   +3 more
doaj   +1 more source

Navigating a Path to Rifampicin Resistance in Tuberculosis

mBio, 2023
For model bacteria, genetic drug resistance usually arises from antibiotic-tolerant subpopulations, but whether this is true for the globally important pathogen Mycobacterium tuberculosis —the cause of tuberculosis—is not known. Here, we discuss a recent article by Sebastian et al. (J. Sebastian, A.
Sakshi Agarwal, Babak Javid
openaire   +5 more sources